China’s Breast Imaging Market, estimated at US$ XX billion in 2024 and 2025, is projected to grow steadily at a CAGR of XX% from 2025 to 2030, ultimately reaching US$ XX billion by 2030.
The global breast imaging market was valued at $4.1 billion in 2022, grew to $4.4 billion in 2023, and is expected to reach $6.6 billion by 2028, with a robust compound annual growth rate (CAGR) of 8.5%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=897
Drivers
The China Breast Imaging Market is primarily driven by the escalating burden of breast cancer across the country, necessitating more frequent and accurate screening and diagnostic procedures. China has witnessed a significant rise in breast cancer incidence, which has led to increased governmental and public health focus on early detection programs. Key government initiatives, such as the nation-wide “Two-Cancer” (breast and cervical cancer) screening expansion, are actively promoting the adoption of breast imaging technologies like mammography, particularly in provincial and rural areas. This push is strongly supported by technological advancements, specifically the shift toward high-precision systems like Full-Field Digital Mammography (FFDM) and 3D Tomosynthesis, which improve diagnostic accuracy and patient outcomes. Furthermore, the growing awareness among the Chinese female population regarding breast health and the benefits of proactive screening is translating into higher patient throughput in hospitals and diagnostic centers. The adoption of advanced systems, fueled by government investment in modernized healthcare infrastructure, forms a robust foundation for market expansion, particularly favoring major international and domestic equipment providers like GE Healthcare, Siemens Healthineers AG, and Fujifilm Holdings Corporation.
Restraints
Despite the strong demand, the China Breast Imaging Market faces several notable restraints that impede faster adoption and market penetration. A major barrier is the high capital expenditure (CapEx) required for sophisticated imaging systems, such as 3D Tomosynthesis and Magnetic Resonance Imaging (MRI) based systems, making them financially prohibitive for many smaller and provincial hospitals. Furthermore, compared to more widely adopted and cheaper alternatives like ultrasound, the high cost of advanced mammography systems limits their widespread deployment. Reimbursement issues also present a significant challenge, as adequate coverage for screening procedures is often insufficient or lacking outside of major urban centers, forcing patients to bear high out-of-pocket costs, which restricts access. Another key restraint is the public perception regarding the risk of radiation exposure associated with ionizing breast imaging technologies, which can lead to patient hesitancy or resistance toward regular mammography screening. Finally, stringent regulations, including the National Medical Products Administration (NMPA) quotas that often favor domestic content and localization, can create hurdles for international manufacturers seeking to expand their market share and integrate cutting-edge technologies.
Opportunities
Significant opportunities exist within the China Breast Imaging Market, primarily centered on expanding access to screening and leveraging digital health integration. A major avenue for growth is the continued national expansion of “Two-Cancer” screening programs, specifically targeting Tier-3/4 cities and rural counties, which creates massive untapped demand for imaging devices, including mobile screening vans. The technological shift towards advanced modalities like 3D mammography (Tomosynthesis) and Automated Breast Ultrasound (ABUS) presents a substantial opportunity for manufacturers offering high-resolution and non-ionizing solutions. Furthermore, the integration of breast imaging platforms with Artificial Intelligence (AI) and Computer-Aided Detection (CAD) systems offers considerable growth potential. AI-powered diagnostics can enhance the efficiency and accuracy of image reading, addressing the shortage of trained radiologists, particularly in remote regions. The market is also primed for growth in ancillary services such as image-guided biopsy systems, which become increasingly critical as early-stage breast cancer detection rates improve. Strategic collaborations between international technology providers and domestic Chinese companies focusing on localized manufacturing and service delivery will be crucial to capitalizing on these evolving market demands.
Challenges
The China Breast Imaging Market confronts several key challenges related to technology adoption, standardization, and regulatory complexity. One core challenge is ensuring equitable access to high-quality breast imaging across the vast and diverse geographic regions of China, as advanced equipment and specialized personnel remain concentrated in major metropolitan areas. Achieving comprehensive coverage requires overcoming logistical hurdles in remote settings and investing heavily in infrastructure and training. Furthermore, integrating new, advanced imaging technologies into existing, often disparate, hospital information systems and workflows can be technically complex and time-consuming. The regulatory landscape, including complex NMPA approval processes for novel medical devices and the pressure from provincial volume-based procurement (VBP) policies that aim to slash system prices, introduces significant market uncertainty and financial pressure on suppliers. Lastly, maintaining the quality and consistency of screening results across various hospital levels and ensuring that AI-CAD systems are rigorously validated for the Chinese population’s specific clinical profile remains an ongoing technical and operational challenge.
Role of AI
Artificial Intelligence (AI) is playing an increasingly critical and transformative role in the China Breast Imaging Market, primarily serving to enhance diagnostic efficiency and accessibility. AI-powered Computer-Aided Detection (CAD) systems are being rapidly adopted, particularly in Class III hospitals, where they assist radiologists in identifying subtle lesions in mammograms with greater speed and consistency. This capability is vital for managing the enormous patient volume associated with nation-wide screening programs and mitigating the impact of radiologist shortages. AI algorithms are also being developed for risk stratification and predicting patient outcomes, moving breast imaging beyond mere detection toward personalized risk management. Furthermore, AI is central to standardizing image quality assessment and optimizing workflow automation, from image acquisition protocols to reporting, which ultimately improves the operational efficiency of breast care centers. The push for widespread AI integration is supported by government policies that prioritize smart healthcare solutions, creating a favorable environment for technological deployment. This pivotal role in streamlining diagnostics and improving accessibility positions AI as a core technology for the future growth and quality control of breast imaging services in China.
Latest Trends
Several dynamic trends are currently shaping the China Breast Imaging Market. A major trend is the accelerating adoption of 3D Mammography (Digital Breast Tomosynthesis or DBT) systems, which offer superior image quality and better cancer detection rates compared to conventional 2D mammography, particularly for women with dense breast tissue. This technological shift is quickly becoming the new standard of care in advanced hospitals. Another significant trend is the rising integration of hybrid imaging solutions, combining modalities like mammography with contrast-enhanced spectral mammography (CESM) or integrating ultrasound/ABUS with traditional screening programs to improve diagnostic confidence. The development and deployment of mobile screening vans equipped with digital mammography technology represent a crucial trend aimed at expanding screening access to underserved populations in rural and lower-tier cities. Furthermore, there is a distinct surge in the development and commercialization of domestically manufactured breast imaging equipment, driven by governmental localization quotas and increasing indigenous R&D capabilities. Finally, the growing focus on personalized screening protocols, tailored based on individual risk factors and breast density, is driving demand for advanced and diverse imaging technologies that can provide more comprehensive risk assessment.